Instagram Facebook Linkedin
Invest Now
NEWS

Autonomix Medical, Inc. Completes Formation of Engineering Development Team and Provides Project Update  

Appointment of Marco Bedoya, a proven leader in medical device mechanical engineering, as Director of Product Development. Engagements secured with preeminent firms to drive design and development of patented two-fold technology designed to detect problematic neural signals and ablate nerves in one simple procedure for pain management. Company on track to complete sensing technology and human clinical trial device development in 1H2025.

SHARE

THE WOODLANDS, TX — January 11, 2024 – Autonomix Medical, Inc. (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the completion of its engineering development team formation and provided an engineering update.  

Lori Bisson, Chief Executive Officer of Autonomix, commented, “We continue to execute on advancing the development of our technology. We have made noteworthy strides and remain on track to evaluate it in our upcoming planned clinical trials. With the appointment of Mr. Bedoya, as well as the engagements we have secured with leading engineering firms, I believe we are in a position to continue the path forward to dramatically improve the quality of millions of lives by empowering the nerve-directed treatments of tomorrow. We are poised for an exciting 2024 and look forward to leveraging the leadership and expertise of the team to provide patients and physicians with a much-needed solution.”

The Company’s catheter-based sensing technology is being developed to do two things: sense neural signals associated with pain or disease and precisely target those nerves for treatment. Autonomix believes this technology is a better alternative to the current approaches commonly used today, where doctors either rely on systemic drugs like opioids that lose effectiveness and have unwanted side effects or treat suspected areas blindly in hopes of hitting the right nerves, an approach that is often inaccurate and can miss the target and even cause collateral damage to surrounding parts of the body. 

To drive the advancement of its proprietary technology, the Company has appointed Marco Bedoya as Director of Product Development. Mr. Bedoya joins Autonomix having most recently served as the Senior R&D Engineer II at Abiomed (acquired by Johnson & Johnson in 2022) where he was responsible for creating the Product Development Roadmap of a Class 3 device product line extension. Prior to that, he served in a number of roles at Hologic, with the most recent being R&D Manager where he provided technical and managerial support for the development and commercialization of a new generation premarket approval (PMA) device and led a cross functional team to develop a class II device from early innovation stages through FDA submission. Prior to that, Mr. Bedoya served as the Sr. Product Development Engineer at Wright Medical Technology.

Mr. Bedoya earned a Bachelor of Science degree in Mechanical Engineering from Universidad de

Costa Rica and a Master of Science degree in Electronics Engineering, Micro-Electromechanical Systems from Instituto Tecnologico de Costa Rica. In addition to his academic accomplishments, Mr. Bedoya holds three registered patents and has published studies focused on Total Joint and Total Ankle replacement.

Additionally, Autonomix has engaged the following engineering firms:

  • Emphysys A Tecan Group Company: Leading global provider blending fundamental science and engineering to deliver limitless technology development. Emphysys brings a team of proven scientists and engineers with deep capabilities and a library of background technologies to take ideas from concept to advanced functional prototype quickly, accurately and cost-effectively with their fixed price engagement model.
  • Sage Product Development: Medical device design, development and manufacturing experts combining a high level of experience with a low overhead company structure to solve technical challenges and meet product development needs in an efficient, highly personalized and cost-effective manner. Specifically, Sage brings a wealth of catheter-development experience to the team.
  • Kaleidoscope Innovation: Provides medical, consumer and industrial clients with full-service insights, design, human factors and product development. For more than 35 years Kaleidoscope has been helping clients grow their capabilities, gain usable knowledge and achieve worthwhile results. As a full-spectrum product design and development firm, Kaleidoscope is an expert extension of your product vision. Their teams collaborate across disciplines, providing specialized input to produce the ideal intersection between function and form. To ensure the soundness of their work, Kaleidoscope houses a full range of test labs and employs an award-winning team that embraces every challenge, applying their experience, ingenuity and passion.

For more information about the Company’s technology, please visit autonomix.com.

About Autonomix Medical, Inc. 


Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class technology platform includes a catheter-based microchip sensing array that has the ability to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.   

We are initially developing our technology for pancreatic cancer pain and pancreatitis pain, conditions that can cause debilitating pain and need an effective solution. However, our technology constitutes a platform with the potential to address dozens of indications, including in cardiology, renal denervation and chronic pain management across a wide disease spectrum.

For more information, visit autonomix.com and connect with the Company on Twitter, LinkedIn and Facebook. 

Forward Looking Statements

Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the ability of Autonomix to successfully develop its technology platform on a timely basis. Such forward-looking statements can be identified by the use of words such as ‘’should,‘’ ‘’may,‘’ ‘’intends,‘’ ‘’anticipates,‘’ ‘’believes,‘’ ‘’estimates,‘’ ‘’projects,‘’ ‘’forecasts,‘’ ‘’expects,‘’ ‘’plans,‘’ and ‘’proposes.‘’

Although Autonomix Medical, Inc. (or Autonomix) believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the offering statement filed with the U.S. Securities and Exchange Commission (“SEC”). Forward-looking statements speak only as of the date of the document in which they are contained and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.

The offering will be made only by means of an offering circular. An offering statement on Form 1-A relating to these securities has been filed with the SEC and has become qualified. The securities offered by Autonomix are highly speculative. Investing in shares of Autonomix involves significant risks. The investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that such investment could be illiquid for an indefinite period of time. No public market currently exists for the securities, and if a public market develops following the offering, it may not continue.

Autonomix intends to list its securities on a national exchange and doing so entails significant ongoing corporate obligations, including but not limited to disclosure, filing and notification requirements, as well compliance with applicable continued quantitative and qualitative listing standards. For additional information on Autonomix, the offering and any other related topics, please review the registration statement that can be found at the following location EDGAR Entity Landing Page (sec.gov). Additional information concerning Risk Factors related to the offering, including those related to the business, government regulations, intellectual property and the offering in general, can be found in the risk factor section of the Form 1-A offering circular.

Investor Relations Contact

JTC Team, LLC

Jenene Thomas 

833-475-8247autonomix@jtcir.com

Stay Up-to-Date With The Future of Autonomix
GET UPDATES

Autonomix Medical, Inc.
21 Waterway Ave, Suite 300
The Woodlands, TX 77380

Instagram Facebook Linkedin

LEGAL DISCLAIMER
This presentation (the “presentation”) has been prepared for use by Autonomix Medical, Inc. (“Autonomix”) in connection with their proposed offering. This presentation is for information purposes only and is being provided to assist interested parties in making their own evaluation with respect to a potential investment, and for no other purpose. This presentation may not be reproduced or redistributed, in whole or in part, without the prior written consent of Autonomix. Autonomix does not make any representation or warranty as to the accuracy or completeness of the information contained in this presentation. This presentation is not intended to be all-inclusive or to contain all the information that a person may desire in considering an investment in connection with the proposed offering and is not intended to form the basis of any investment decision. You should consult your own legal, regulatory, tax, business, financial and accounting advisors to the extent you deem necessary and must make your own investment decision and perform your own independent investigation and analysis of an investment in the transactions contemplated in this presentation.

NEITHER THE SECURITIES AND EXCHANGE COMMISSION (“SEC”) NOR ANY STATE OR TERRITORIAL SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THE SECURITIES OR DETERMINED IF THIS PRESENTATION IS TRUTHFUL OR COMPLETE.

FORWARD-LOOKING STATEMENTS
This presentation may include ‘’forward-looking statements.‘’ To the extent that the information presented in this presentation discusses financial projections, information, or expectations about Autonomix Medicial, Inc.’s business plans, results of operations, products or markets, or otherwise makes statements about future events, such statements are forward-looking. Such forward-looking statements can be identified by the use of words such as ‘’should,‘’ ‘’may,‘’ ‘’intends,‘’ ‘’anticipates,‘’ ‘’believes,‘’ ‘’estimates,‘’ ‘’projects,‘’ ‘’forecasts,‘’ ‘’expects,‘’ ‘’plans,‘’ and ‘’proposes.‘’

Although Autonomix Medical Inc. (or Autonomix) believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the offering statement filed with the SEC. Forward-looking statements speak only as of the date of the document in which they are contained, and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.

The offering will be made only by means of an offering circular. An offering statement on Form 1-A relating to these securities has been filed with the U.S. Securities and Exchange Commission and has become qualified. The securities offered by Autonomix are highly speculative. Investing in shares of Autonomix involves significant risks. The investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that such investment could be illiquid for an indefinite period of time. No public market currently exists for the securities, and if a public market develops following the offering, it may not continue.

Autonomix intends to list its securities on a national exchange and doing so entails significant ongoing corporate obligations including but not limited to disclosure, filing and notification requirements, as well compliance with applicable continued quantitative and qualitative listing standards. For additional information on Autonomix, the offering and any other related topics, please review the registration statement that can be found at the following location EDGAR Entity Landing Page (sec.gov). Additional information concerning Risk Factors related to the offering, including those related to the business, government regulations, intellectual property and the offering in general, can be found in the risk factor section of the Form 1-A offering circular.

USE OF DATA
The data contained herein is derived from various internal and external sources. No representation is made as to the reasonableness of the assumptions made within or the accuracy or completeness of any projections or modeling or any other information contained herein. Any data on past performance or modeling contained herein is not an indication as to future performance. Autonomix assumes no obligation to update the information in this presentation.

© 2023 Autonomix Medical, Inc. All rights reserved.
Privacy Policy

Autonomix is committed to protecting your privacy. This Privacy Policy outlines our practices concerning the collection, use, and protection of your personal information when you visit our website or use our services.

1. Information We Collect

We may collect personal information that you voluntarily provide to us, including but not limited to:

  • Name
  • Email address
  • Contact information
  • Billing and payment details
  • User-generated content (e.g., comments, reviews)

We may also collect non-personal information, such as:

  • Browser type
  • IP address
  • Device information
  • Cookies and usage data

2. How We Use Your Information

We may use your personal information for various purposes, including but not limited to:

  • Providing, maintaining, and improving our website and services.
  • Processing transactions and payments.
  • Sending updates, newsletters, and promotional materials.
  • Responding to your inquiries and requests.
  • Complying with legal obligations.


3. Cookies and Tracking Technologies

We use cookies and similar tracking technologies to collect information about your browsing behavior on our website. You can manage your cookie preferences through your browser settings.

4. Disclosure of Your Information

We may share your personal information with third parties under the following circumstances:

  • With your consent.
  • To comply with legal obligations.
  • To protect our rights, privacy, safety, or property.
  • In connection with the sale, merger, or acquisition of all or part of our business.

5. Your Rights

You have the right to:

  • Access, update, or delete your personal information.
  • Object to the processing of your personal information.
  • Withdraw your consent, where applicable.
  • Lodge a complaint with a supervisory authority.

6. Data Security

We take reasonable measures to protect your personal information from unauthorized access, disclosure, alteration, or destruction. However, no method of data transmission over the internet or electronic storage is entirely secure. Therefore, we cannot guarantee its absolute security.

7. Children’s Privacy

Our website and services are not intended for children under the age of 13. We do not knowingly collect personal information from children. If you believe that a child has provided us with their personal information, please contact us, and we will take appropriate steps to delete the information.

8. Changes to this Privacy Policy

We may update this Privacy Policy from time to time to reflect changes in our practices or for other operational, legal, or regulatory reasons. We encourage you to review this Privacy Policy periodically for any updates.

9. Contact Us

If you have any questions or concerns about this Privacy Policy or our data practices, please contact us at autonomix@jtcir.com.

Terms & Conditions

1. Acceptance of Terms

By accessing and using this website, you agree to abide by these Terms and Conditions, as well as any applicable laws and regulations. If you do not agree with these terms, please refrain from using this website.

2. Use of Content

All content on this website, including but not limited to text, images, graphics, videos, and logos, is the property of Autonomix or its affiliates and is protected by intellectual property laws. You may not reproduce, distribute, or display any content without prior written permission.

3. User Conduct

You agree not to engage in any of the following activities while using this website:

  • Violating any applicable laws or regulations.
  • Uploading or transmitting any content that is harmful, offensive, or infringing on the rights of others.
  • Attempting to gain unauthorized access to the website, its servers, or user data.
  • Interfering with the website’s functionality or security.

4. Privacy Policy

Your use of this website is also governed by our Privacy Policy, which outlines how we collect, use, and protect your personal information. By using this website, you consent to the practices described in our Privacy Policy.

5. Links to Third-Party Websites

This website may contain links to third-party websites. These links are provided for convenience only, and Autonomix does not endorse or assume responsibility for the content or practices of these websites. Accessing third-party websites is at your own risk.

6. Disclaimer of Warranties

This website is provided “as is,” without any warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose, or non-infringement. Autonomix does not warrant that the website will be error-free or uninterrupted.

7. Limitation of Liability

To the fullest extent permitted by law, Autonomix shall not be liable for any direct, indirect, incidental, consequential, or punitive damages arising out of or related to your use of this website. This includes but is not limited to any loss of data or profits.

8. Governing Law

These Terms and Conditions shall be governed by and construed in accordance with the laws of the United States. Any disputes arising under these terms shall be subject to the exclusive jurisdiction of the courts in the United States.

9. Changes to Terms and Conditions

Autonomix reserves the right to modify or revise these Terms and Conditions at any time. It is your responsibility to review this page periodically for updates. Your continued use of the website after any changes signifies your acceptance of the revised terms.

10. Contact Information

If you have any questions or concerns about these Terms and Conditions, please contact us at autonomix@jtcir.com.

Be The First To Get Updates About Autonomix
Skip to content